Back

FDA Approves Livsayis for Generalized Myasthenia Gravis

Regeneron’s Livsayis (cemdisiran) received U.S. Food and Drug Administration approval on November 18, 2026, according to the agency’s novel-drug list. The approval covers adults with generalized myasthenia gravis, or gMG, whose tests show antibodies against the acetylcholine receptor (AChR.

Regeneron said Livsayis is the first siRNA therapy approved for gMG. According to the company, the approved dosing schedule calls for a healthcare professional to administer 567 mg beneath the skin at three-month intervals.

The prescribing information includes a boxed warning about an increased risk of meningococcal infection that can be serious and life-threatening. Under the label, access is limited through a risk-management program, and patients must receive meningococcal vaccination before starting treatment when feasible. For urgent treatment before vaccination is current, the label specifies preventive antibiotics and vaccination at the earliest opportunity.

In Regeneron’s account of anti-AChR gMG, antibodies trigger the complement system, including the C5 protein, disrupting communication between nerves and muscles. The company said the disease can impair movement, vision, speech, breathing and swallowing.

According to the prescribing information, cemdisiran acts through RNA interference, breaking down the messenger RNA used to make C5. This lowers both C5 production in the liver and the amount circulating in the body, inhibiting terminal complement activity. The document states that exactly how the drug produces its therapeutic effect in gMG remains unknown. It identifies less C5b-9 deposition where nerves meet muscles as a presumed explanation, rather than an established mechanism.

A study lasting 24 weeks supported the approval, according to the prescribing information. Participants were randomly assigned to Livsayis or placebo under double-blind conditions. By week 24, daily-function scores measured with MG-ADL had improved from baseline by an average of 4.5 points in the Livsayis group, compared with 2.2 points in the placebo group. On the QMG measure of muscle function, average improvements were 4.2 points and 1.5 points, respectively. Those figures describe trial outcomes, not an assurance of any individual patient’s response.

The first-siRNA designation does not identify Livsayis as the first FDA-approved treatment for the condition. The agency’s 2026 novel-drug list also includes Klygefa, with a November 13, 2026, approval for anti-AChR antibody-positive gMG.

* This article is based on publicly available information at the time of writing.